Paw Hepatoadvanced Cats and Small Dogs Under 15kg (60 Tablets) LOWER STRENGTH FORMULATION

In this NEW formulation Blackmore's has improved the ease of administration without compromising on therapeutic efficacy. They have achieved this by crafting a smaller and easier-to-give format that aids in the management of compromised liver biomarkers in cats and dogs.

PAW Hepatoadvanced is a convenient, chewable tablet containing a blend of bioavailable antioxidants, providing detoxification support in the management of canine and feline liver disease via the following means:

• Supports the production of glutathione
• Promotes liver detoxification
• May protect against negative effects on the liver caused by some medications
• Supports liver health in pets presenting with acute liver toxicity
• Supports brain health in dogs

 *DO NOT exceed 2 chewable tablets per day. For optimal absorption, administer Hepatoadvanced (as per the dosing chart above), once a day on an empty stomach.

The recommended total daily dose for dogs and cats is SAMe 10- 20mg/kg, SPC 2.7- 5.4mg/kg and vitamin E 10-15IU/kg.

Features and Benefits

• Simple and convenient dosing in the form of a tasty chewable tablet
• Formulated with delayed release technology, enabling steady metabolism by the liver and a prolonged duration of activity
• Contains a unique and stable form of S-adenosylmethionine (SAMe), a precursor to the potent antioxidant glutathione, which is hepatoprotective.
• Contains silybin in a phospholipid complex, which has been shown to provide significantly enhanced bioavailability in dogs and cats compared to standardised milk thistle
• Contains vitamin E in its formulation, preventing the need for additional supplementation

Hepatoadvanced may be used as an adjunctive therapy in conditions such as:

• Chronic hepatitis
• Hepatic lipidosis
• Cholangiohepatitis
• Paracetamol toxicity
• Hepatotoxic mushroom ingestion
• Copper related hepatopathy
• Iron overload - Medication use including NSAIDs, phenobarbital and corticosteroids (note: does not prevent corticosteroid-induced hepatic vacuolar change)
• Metabolic hepatopathies
• Other acute or chronic hepatopathies
• Neoplasia
• Canine cognitive dysfunction
• Cirrhosis

Hepatoadvanced can be used concomitantly with other common hepatic supportive treatments, such as prescription diets, ursodeoxycholic acid, anti-inflammatories, and other non-vitamin E containing nutritional supplements. Regular re-assessment (e.g. every 1-3 months) is recommended to ensure the optimal dose is achieved to reach the desired therapeutic outcome.

Warnings/ Safety 

• For animal use only.
• For veterinary supply only.
• Use with caution in pregnant or lactating animals as safe use has not been established in this population
• SAMe has a wide safety margin. Side effects or overdose effects are rare, but are limited to mild gastrointestinal signs, immediate post pill nausea and food refusal.Concomitant use of SAMe with tramadol, meperidine, dextromethorphan, pentazocine, MAOIs (selegiline), SSRIs (fluoxetine), other antidepressants (amitriptyline, clomipramine) may theoretically cause additive serotonergic effects. Use with caution simultaneously.
• Silymarin typically has no side effects, but consider drug interactions in polymedicated patients, such as the following: antiviral drugs, drugs affected by cytochrome P450 & CYP3A4 inhibition and drugs cleared via hepatic glucuronidation.
• There are no commonly noted toxic effects derived from vitamin E supplementation, although it may inhibit the absorption of other fat- soluble vitamins when administered at high doses. Therefore, it is recommended to not exceed a total daily dose of 400IU per dog. Vitamin E is not recommended in liver disease patients with evidence of vitamin K deficiency.

Storage: Store below 25°C in a dry place away from sunlight

Size: 30 chewable tablets

Expiry: 24 months from manufacture